Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2019-11-01
|
| Schriftenreihe: | Pharmaceuticals |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/1424-8247/12/4/165 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|